Global Diabetic Nephropathy Market

Diabetic Nephropathy Market Size, Share, Growth Analysis, By Type(Pharmaceutical Therapy, and Renal Replacement Therapy.), By Application(Hospitals, Specialty Clinics, and Others), By Diagnostic Methods(Blood Tests, Urine Tests, and Imaging Techniques.), By Region - Industry Forecast 2024-2031

Report ID: SQMIG35D2095 | Region: Global | Published Date: February, 2024
Pages: 157 | Tables: 89 | Figures: 76

Diabetic Nephropathy Market News

  • In March 2023, Novartis announced that it had submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for renoprotective effects of sevelamer carbonate, a phosphate binder, for the treatment of diabetic nephropathy.
  • In January 2022, AstraZeneca announced that it had initiated a Phase 2 clinical trial of dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for the treatment of diabetic nephropathy.
  • In September 2021, Mitsubishi Tanabe Pharma announced that it had entered into a licensing agreement with Innovent Biologics for the development and commercialization of moxetumomab pasudotox-tdfk, an anti-CD20 antibody-drug conjugate, for the treatment of diabetic nephropathy.
  • In May 2021, Eli Lilly and Company announced that it had initiated a Phase 3 .clinical trial of tirzepatide, a novel GLP-1 receptor agonist and GIP receptor agonist, for the treatment of diabetic nephropathy.In February 2021, Sanofi announced that it had submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for fostamatinib, a novel JAK inhibitor, for the treatment of diabetic nephropathy.
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.



Diabetic Nephropathy Market size was valued at USD 1.9 billion in 2021 and is poised to grow from USD 2.01 billion in 2022 to USD 3.21 billion by 2030, growing at a CAGR of 6% in the forecast period (2023-2030).

The diabetic nephropathy market is characterised by intense competition among key players aiming to capture a significant market share. Diabetic nephropathy refers to kidney damage caused by diabetes, and the market encompasses a wide range of treatment options, including medications, dialysis, and kidney transplant. This competitive landscape provides a general overview of the market dynamics without mentioning any specific company names. 'Novartis AG (Switzerland)', 'Merck & Co., Inc. (US)', 'Pfizer Inc. (US)', 'Johnson & Johnson (US)', 'Sanofi S.A. (France)', 'AstraZeneca PLC (United Kingdom)', 'Boehringer Ingelheim International GmbH (Germany)', 'AbbVie Inc. (US)', 'Eli Lilly and Company (US)', 'Bristol Myers Squibb Company (US)', 'GlaxoSmithKline PLC (United Kingdom)', 'Novo Nordisk A/S (Denmark)', 'Bayer AG (Germany)', 'Amgen Inc. (US)', 'Takeda Pharmaceutical Company Limited (Japan)', 'Astellas Pharma Inc. (Japan)', 'Daiichi Sankyo Company, Limited (Japan)', 'Mitsubishi Tanabe Pharma Corporation (Japan)', 'Fresenius Medical Care AG & Co. KGaA (Germany)', 'Otsuka Pharmaceutical Co., Ltd. (Japan)'

The escalating healthcare expenditure, particularly in emerging economies, significantly contributes to the expansion of the diabetic nephropathy market. Increased healthcare funding enables enhanced accessibility to healthcare facilities, diagnostics, medications, and treatment options for individuals with diabetic nephropathy.

Development of New and More Effective Treatments: The rising cost of healthcare, and the growing demand for personalised medicine stands as key market trends. As the market continues to grow, we can expect to see more innovation in the treatment of diabetic nephropathy, and this innovation is expected to help improve the lives of people with this condition.

North America holds a prominent position in the diabetic nephropathy market. The region is characterised by well-developed electricity infrastructure, a mature market, and a high level of consumer awareness and engagement. The US and Canada are major contributors to the region's dominance, with a strong emphasis on clean energy sources, smart grid systems, and customer-centric retail electricity services. The market in North America is supported by favourable government policies, including incentives for renewable energy adoption and energy efficiency programs. Additionally, the presence of established retail electricity providers and a competitive market landscape contribute to the dominance of North America in the Diabetic Nephropathy market.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.


Feedback From Our Clients

Global Diabetic Nephropathy Market

Report ID: SQMIG35D2095